Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Candin versus placebo for common warts
jRCT2031230342Phase 3Completed
- Sponsor
- Nielsen BioSciences, Inc.
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in common wart comparing Candin with Placebo (2 arms). Primary endpoint: Complete resolution of the treatment wart without recurrence. Started Mar 2024; status: completed.
02
Drugs
candida albicans antigen
03
Conditions
common wart
Beyond the preview
Go deeper on jRCT2031230342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230342.